Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET
Company Participants
Yoshimasa Kyokawa – Vice President, Corporate Communications
Isao Teshirogi – Chairman, President, and CEO
John Keller – Senior Vice President, R&D, Supervisory Unit
Takeki Uehara – Senior Vice President, Drug Development and Regulatory Science Division
Toshinobu Iwasaki – Senior Vice President, Healthcare Business Unit
Koji Hanasaki – Senior Vice President, Supply Supervisory Unit, Global Business Division
Masako Kudou – Vice President, Finance and Accounting Department
Conference Call Participants
Hidemaru Yamaguchi – Citi
Eiji Ueda – Goldman Sachs
Kasumi Haruta – UBS
Kazuaki Hashiguchi – Daiwa Securities
Seiji Wakao – JPMorgan
Shinya Tsuzuki – Mizuho Securities
Miki Sogi – Bernstein
Hiroyuki Matsubara – Nomura Securities
Yoshimasa Kyokawa
Ladies and gentlemen, time to start today’s meeting. I am Kyokawa, the Head of Public Relations Department at the Shionogi & Co. Thank you very much for taking time to join us today. We will now begin the Shionogi & Co., Ltd. Second Quarter Financial Results Briefing for Fiscal Year 2024.
First of all, let me introduce our speakers for today. Isao Teshirogi, Chairman, President, and CEO And next, Mr. John Keller, Senior Vice President, R&D, Supervisory Unit; very nice to see you. Next, Mr. Toshinobu Iwasaki, Senior Vice President, Healthcare Business Unit. Hi, Iwasaki, very nice to see you. And then next, Mr. Koji Hanasaki, Senior Vice President, Supply Supervisory Unit, Global Business Division; very nice to see you. Next, Mr. Takeki Uehara, Senior Vice President, Drug Development and Regulatory Science Division; nice to see you. Lastly, Ms. Masako Kudou, Vice President, Finance and Accounting Department.
Today we will begin with the overview of the financial result followed by the presentation initiatives for achieving the 2030 Vision given by Mr. Teshirogi, Mr. John Keller, Mr. Uehara and Mr. Iwasaki in this
